-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42

Benzinga·05/26/2026 17:03:54
Listen to the news
Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.